Systematic review of LHRH agonists for the adjuvant treatment of early breast cancer

Breast

Volumn 14, Issue 3, 2005, Pages 181-191

  Sharma, Rohini ^a   Beith, Jane ^a   Hamilton, Anne ^a  

^a SYDNEY CANCER CENTRE   (Australia)

Author keywords

Adjuvant therapy; Breast Carcinoma; LHRH agonists

Indexed keywords

ANASTROZOLE; BUSERELIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; METHOTREXATE; TAMOXIFEN; TRIPTORELIN;

AMENORRHEA; BODY WEIGHT DISORDER; BONE DISEASE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; DRUG UTILIZATION; EARLY CANCER; FOLLOW UP; HOT FLUSH; HUMAN; LEUKOPENIA; MEDICAL DECISION MAKING; META ANALYSIS; NAUSEA AND VOMITING; NEUTROPENIA; OVARIECTOMY; OVARY FUNCTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VAGINA DISCHARGE; VAGINA DISEASE; WEIGHT GAIN;

EID: 19644382556     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2005.02.001     Document Type: Review

References (30)

1. Ferlay JBF, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC CancerBase No. 5, IARCPress. 2001.
2. P. Pujol J.P. Daures S. Thezenas et al. Changing estrogen and progesterone receptor patterns in breast caner carcinoma during the menstrual cycle and menopause Cancer 83 1998 698-705
3. J.G. Klijn R.W. Blamey F. Boccardo T. Tominaga L. Duchateau R. Sylvester Combined TAM and luteinising hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in pre-menopausal advanced breast cancer: A meta-analysis of four randomised trial J Clin Oncol 19 2 2001 343-353
4. J. Bines D.M. Oleske M.A. Cobleigh Ovarian function in pre-menopausal women treated with adjuvant chemotherapy for breast cancer J Clin Oncol 14 1996 1718-1729
5. J.A. Soreide J.E. Varhaug H.E. Fjosne B. Erikstein A.B. Jacobsen E. Skovland et al. Adjuvant endocrine treatment (goserelin vs. TAM) in pre-menopausal patients with operable node positive stage II breast cancer: A prospective randomised national multicenter study Eur J Surg Oncol 28 5 2002 505-510
6. O. Pagani A. O'Neil M. Castiglione et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in pre-menopausal breast cancer patients with axillary node involvement: Results of the International Breast Cancer Study Group (IBCSG) Trial VI Eur J Cancer 34 1998 632-640
7. Early Breast Cancer Trialists' Collaborative Group Ovarian ablation in early breast cancer: Overview of the randomised trails Lancet 348 1996 1189-1196
8. Scottish Cancer Trials Breast Group (SCTBG) and ICRF Breast Unit, Guy's Hospital, London Adjuvant ovarian ablation versus CMF in pre-menopausal women with pathological stage II breast carcinoma: The Scottish trial Lancet 341 1993 1293-1299
9. B. Ejlertsen P. Dombernowsky H.T. Mouridsen C. Kamby M. Kjaer C. Rose et al. Comparable effect of ovarian ablation (OA) and CMF chemotherapy in pre-menopausal hormone receptor positive breast cancer patients Proc Am Soc Clin Oncol 18 1999 (Abstr 248)
10. M. Baum J. Houghton W. Sawyer W. Odling-Smee L.E. Rutqvist B. Nordenskjold et al. Management of pre-menopausal women with early breast cancer: Is there a role for goserelin? Proc Am Soc Clin Oncol 21 2001 (Abstr 103)
11. N.E. Davidson A. O'Neill A. Vukov C.K. Osborne S. Martino D. White et al. Chemohormonal therapy in pre-menopausal node-positive, receptor positive breast cancer: An Eastern Cooperative Oncology Group phase III intergroup trial (E5188, INT-0101) Proc Am Soc Clin Oncol 22 2003 (Abstr 15)
12. J.W.M. Liddle L. Irwig Method for evaluating research and guideline evidence 1996 NSW Health Department Sydney
13. H. Roche P. Kerbrat J. Bonneterre P. Fargeot P. Fumoleau A. Monnier et al. Complete hormonal blockade versus chemotherapy in pre-menopausal early stage breast cancer patients (pts) with positive hormone-receptor (HR+) and 1-3 node-positive (N+) tumor: Results of the FASG 06 trial Proc Am Soc Clin Oncol 2000 (Abstr 279)
14. A.R. Bianco R. Costanzo G. Di Lorenzo V. Adamo G. Altavilla M. D'Aprile et al. The MAM-1 GOCSI trial: A randomised trial with factorial design of chemo-endocrine adjuvant treatment in node positive (N+) early breast cancer (ebc) Proc Am Soc Clin Oncol 20 2001 (Abstr 104)
15. C.I. Falkson R. Jooste H.C. Falkson G. Falkson D. Rens R. van Aarde et al. Cyclophosphamide, methotrexate and fluorouracil (CMF) plus or minus depo-buserelin in pre-menopausal women with lymph node positive breast cancer Proc Am Soc Clin Oncol 2001 (Abstr 1777)
16. W. Jonat M. Kaufmann R. Sauerbrei R. Blamey J. Cuzik M. Namer et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in pre-menopausal patients with node-positive breast cancer: The zoladex early breast cancer research association study J Clin Oncol 20 24 2002 4628-4635
17. International Breast Cancer Study Group Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: A randomised trial J Nat Cancer Inst 95 24 2003 1833-1846
18. P. Schmid M. Untch D. Wallwiener V. Kosse G. Bondar L. Vassiljev et al. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: Preliminary results of the TABLE-study (Takeda Adjuvant Breast Cancer Study with Leuprorelin acetate) Anticancer Res 22 2002 2325-2332
19. R. Jakesz H. Hausmaninger E. Kubista M. Gnant C. Menzel T. Bauernhofer et al. Randomised adjuvant trial of TAM and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: Evidence for the superiority of treatment with endocrine blockade in pre-menopausal patients with hormone responsive breast cancer - Austrian breast and colorectal cancer study group trial 5 J Clin Oncol 20 24 2002 4621-4627
20. F. Boccardo D. Rubagotti A Amoroso M. Mesiti D. Romeo P. Sismondi et al. Cyclophosphamide, methotrexate and fluorouracil versus TAM plus ovarian suppression as adjuvant treatment of oestrogen receptor-positive pre-/ peri menopausal breast cancer patients: Results of the Italian breast cancer adjuvant study group 02 randomised trial J Clin Oncol 18 14 2000 2718-2727
21. M. Nystedt G. Berglund C. Bolund T. Fornander L.E. Rutqvist Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective randomised study J Clin Oncol 21 9 2003 1836-1844
22. R. Blamey I. Fogelman Reversibility of bone mineral density loss in pre-/ peri menopausal patients with node-positive early breast cancer after treatment with Zoladex™: Results from the ZEBRA study Breast Cancer Res Treatment 69 2001 (Abstr 244)
23. J.C. De Haes M. Olschewski W. Jonat M. Kaufmann W. Jonat Quality of life (QL) assessment in an international randomised trial: Temporary ovarian ablation vs. CMF in early breast cancer Eur J Cancer 30 Suppl 2 1994
24. Untch M, Kahlert S, Kosse V, Bondar G, Kienle E, Maubach L, Schmid P, Wallwiener D, et al. LHRH-analogue therapy with leuprorelin-acetate three-month depot offers similar efficacy to conventional adjuvant CMF chemotherapy in receptor positive, node positive Breast Cancer patients. In: San Antonio breast cancer symposium, San Antonio, TX, 2003 (Abstr 40).
25. French Adjuvant Study Group Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French adjuvant study group 05 randomized trial J Clin Oncol 19 2001 602-611
26. S. Aebi S. Belber M. Castiglione-Gertsch R.D. Gelber J. Collins et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 355 2000 1869-1874
27. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group Anastrazole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial Lancet 359 2002 2131-2139
28. National Institutes of Health Consensus Development Panel National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast Cancer JNCI 93 2001 979-989
29. A. Goldhirsch J.H. Glick R.D. Gelber A.S. Coates J. Senn H- Meeting highlights: International consensus panel on the treatment of primary breast cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer J Clin Oncol 19 2001 3817-3827
30. R.W. Blamey Guidelines on endocrine therapy of breast cancer - EUSOMA Eur J Cancer 38 2001 615-634